Fluoxetine increases the content of neurotrophic protein S100β in the rat hippocampus

doi:10.1016/S0014-2999(01)00989-X

European Journal of Pharmacology

Volume 420, Issues 2–3, 25 May 2001, Pages R1-R2

https://doi.org/10.1016/S0014-2999(01)00989-X Get rights and content

Abstract

Recent studies indicate that a protracted daily administration of the antidepressant fluoxetine to adult rats increases cell proliferation/neurogenesis in the hippocampus. It has been hypothesized that this action of fluoxetine might be mediated by neurotrophic factors. We hypothesized that glial S100β could be such a factor, and using quantitative Western immunoblotting, we investigated the effect of a 21-day treatment of rats with fluoxetine (5 mg/kg), and found that fluoxetine increases the content of hippocampal S100β.

Section snippets

Acknowledgements

This work was supported in part by the 2000 NARSAD Independent Investigator Award to H. Manev.

References (8)

B. Ahlemeyer et al.
S-100beta protects cultured neurons against glutamate- and staurosporine-induced damage and is involved in the antiapoptotic action of the 5 HT(1A)-receptor agonist, Bay ×3702
Brain Res.
(2000)
J.H. Haring et al.
Hippocampal serotonin levels influence the expression of S100 beta detected by immunocytochemistry
Brain Res.
(1993)
H.J. Huttunen et al.
Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation
J. Biol. Chem.
(2000)
H. Manev et al.
Antidepressants alter cell proliferation in the adult brain in vivo and in neural cultures in vitro
Eur. J. Pharmacol.
(2001)

There are more references available in the full text version of this article.

Cited by (81)

Molecular aspects of depression: A review from neurobiology to treatment
2019, European Journal of Pharmacology
Citation Excerpt :
Neurogenesis is significantly increased in hippocampal neurons after chronic treatment with antidepressants. Research has evidenced this effect only in the dentate gyrus of the hippocampus (Surget et al., 2008), which occurs not only after treatment with classic antidepressants available on market, but also with classes of drugs very different from antidepressants, including drugs that act on monoaminergic targets (Malberg et al., 2000; Manev et al., 2001), glutamatergic (Yoshimizu and Chaki, 2004), cannabinoid targets (Jiang et al., 2005), as well as compounds acting on the HPA axis such as corticotrophin CRF1 receptor antagonists, vasopressin V1b (Alonso et al., 2004), and the Major Complex of Histocompatibility (MCH) (David et al., 2007). Rodents submitted to treatments with effects similar to those of antidepressants, such as physical exercises (Kronenberg et al., 2003; van Praag et al., 1999) and environment enrichment (Kronenberg et al., 2003; Schloesser et al., 2010; Veena et al., 2009), have also demonstrated induction of neurogenesis.
Major depressive disorder (MDD), also known as unipolar depression, is one of the leading causes of disability and disease worldwide. The signs and symptoms are low self‑esteem, anhedonia, feeling of worthlessness, sense of rejection and guilt, suicidal thoughts, among others. This review focuses on studies with molecular-based approaches involving MDD to obtain an integrated, more detailed and comprehensive view of the brain changes produced by this disorder and its treatment and how the Central Nervous System (CNS) produces neuroplasticity to orchestrate adaptive defensive behaviors. This article integrates affective neuroscience, psychopharmacology, neuroanatomy and molecular biology data. In addition, there are two problems with current MDD treatments, namely: 1) Low rates of responsiveness to antidepressants and too slow onset of therapeutic effect; 2) Increased stress vulnerability and autonomy, which reduces the responses of currently available treatments. In the present review, we encourage the prospection of new bioactive agents for the development of treatments with post-transduction mechanisms, neurogenesis and pharmacogenetics inducers that bring greater benefits, with reduced risks and maximized access to patients, stimulating the field of research on mood disorders in order to use the potential of preclinical studies. For this purpose, improved animal models that incorporate the molecular and anatomical tools currently available can be applied. Besides, we encourage the study of drugs that do not present "classical application" as antidepressants, (e.g., the dissociative anesthetic ketamine and dextromethorphan) and drugs that have dual action mechanisms since they represent potential targets for novel drug development more useful for the treatment of MDD.
Hippocampal astrocyte atrophy in a mouse depression model induced by corticosterone is reversed by fluoxetine instead of benzodiazepine diazepam
2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry
Astrocytes have become promising new agents against major depressive disorders (MDD) primarily due to the crucial role they play in the pathogenesis of such disorders. However, a simple and reliable animal model that can be used to screen for astrocyte-targeting antidepressants has not yet been developed. In this study, we utilized a repeated corticosterone (CORT) injection paradigm to develop a mouse depression model wherein we examined the occurrence of alterations in hippocampal astrocyte population by using two astrocytic markers, namely, glial fibrillary acidic protein (GFAP) and S100β. Moreover, we determined the effects of fluoxetine and diazepam on CORT-induced astrocytic alterations to assess the predictive validity. Results showed that repeated CORT injections showed no effects on the number of GFAP⁺ and S100β⁺ astrocytes, but they decreased the protrusion length of GFAP⁺ astrocytes and GFAP protein expression in the hippocampus. Furthermore, repeated CORT injections produced a sustained increase of S100β protein levels in the entire hippocampus of male mice. CORT-induced hippocampal astrocyte disruption was antagonized by chronic fluoxetine treatment. By contrast, the anxiolytic drug diazepam was ineffective in the same experimental setting. All these findings suggest that the repeated CORT injection paradigm produces the astrocytic alterations similar to those in MDD and can serve as a useful mouse model to screen antidepressants meant to target astrocytes. These observations can also help in further discussing the underlying mechanisms of CORT-induced astrocytic alterations.
Antidepressant and pro-neurogenic effects of agmatine in a mouse model of stress induced by chronic exposure to corticosterone
2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry
Agmatine is an endogenous neuromodulator that has been shown to have beneficial effects in the central nervous system, including antidepressant-like effects in animals. In this study, we investigated the ability of agmatine (0.1 mg/kg, p.o.) and the conventional antidepressant fluoxetine (10 mg/kg, p.o.) to reverse the behavioral effects and morphological alterations in the hippocampus of mice exposed to chronic corticosterone (20 mg/kg, p.o.) treatment for a period of 21 days as a model of stress and depressive-like behaviors. Chronic corticosterone treatment increased the immobility time in the tail suspension test (TST), but did not cause anhedonic-like and anxiety-related behaviors, as assessed with the splash test and the open field test (OFT), respectively. Of note, the depressive-like behaviors induced by corticosterone were accompanied by a decrease in hippocampal cell proliferation, although no changes in hippocampal neuronal differentiation were observed. Our findings provide evidence that, similarly to fluoxetine, agmatine was able to reverse the corticosterone-induced depressive-like behaviors in the TST as well as the deficits in hippocampal cell proliferation. Additionally, fluoxetine but not agmatine, increased hippocampal differentiation. Agmatine, similar to fluoxetine, was capable of increasing both dendritic arborization and length in the entire dentate hippocampus, an effect more evident in the ventral portion of the hippocampus, as assessed with the modified Sholl analysis. Altogether, our results suggest that the increase in hippocampal proliferation induced by agmatine may contribute, at least in part, to the antidepressant-like response of this compound in this mouse model of stress induced by chronic exposure to corticosterone.
Serotonin transporter and receptor ligands with antidepressant activity as neuroprotective and proapoptotic agents
2017, Pharmacological Reports
Serotonin exhibits multiple non-neural functions involved in essential hypertension, early embryogenesis, follicle maturation and behaviour. The growth stimulatory effects of the neurotransmitter have been described for a variety of cell types. 5-HT was found to induce migration of the human prostate cancer cell lines – PC-3 and Du145 – and several 5-HT_1A antagonists and serotonin reuptake inhibitors were reported to inhibit the growth of different tumour cell lines in vitro. Recent studies suggest that neurogenesis is involved in the action of antidepressants and an involvement of antidepressants in adult hippocampal neurogenesis has been demonstrated. Antidepressants also exhibit neuroprotective activity, which could be connected to their antidepressant activity. However, it has been reported that certain antidepressants may induce apoptosis in some cancer cell lines. In the present paper the neuroprotective and proapoptotic activities of serotonergic antidepressants (SSRIs and TCAs), as well as 5-HT_1A receptor ligands are summarized and discussed based on biochemical transduction pathways associated with these activities.
The role of adult neurogenesis in psychiatric and cognitive disorders
2017, Brain Research
Neurogenesis in mammals occurs throughout life in two brain regions: the ventricular–subventricular zone (V–SVZ) and the subgranular zone (SGZ) of the hippocampal dentate gyrus. Development and regulation of the V–SVZ and SGZ is unique to each brain region, but with several similar characteristics. Alterations to the production of new neurons in neurogenic regions have been linked to psychiatric and neurodegenerative disorders. Decline in neurogenesis in the SGZ correlates with affective and psychiatric disorders, and can be reversed by antidepressant and antipsychotic drugs. Likewise, neurogenesis in the V–SVZ can also be enhanced by antidepressant drugs. The regulation of neurogenesis by neurotransmitters, particularly monoamines, in both regions suggests that aberrant neurotransmitter signaling observed in psychiatric disease may play a role in the pathology of these mental health disorders. Similarly, the cognitive deficits that accompany neurodegenerative disease may also be exacerbated by decreased neurogenesis. This review explores the regulation and function of neural stem cells in rodents and humans, and the involvement of factors that contribute to psychiatric and cognitive deficits.
This article is part of a Special Issue entitled SI:StemsCellsinPsychiatry.
Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice
2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry
Citation Excerpt :
Newborn neurons contribute to enhanced neural plasticity, which can sustain specific brain functions, such as spatial learning and mood regulation (Santarelli et al., 2003; Llorens-Martin et al., 2006). Antidepressant drugs and lithium are used to treat mood disorders and have been shown to increase cell proliferation and perhaps promote the subsequent survival of hippocampal neurons, indicating that increased hippocampal neurogenesis may be a common action of antidepressant treatment (Malberg et al., 2000; Chen et al., 2000; Manev et al., 2001). Non-antidepressant psychotropics, such as haloperidol or opioids, have no effect on or even decrease hippocampal neurogenesis (Eisch et al., 2000; Malberg et al., 2000; Benninghoff et al., 2013).
Therapeutic effects of antidepressants and atypical antipsychotics may arise partially from their ability to stimulate neurogenesis. Cannabidiol (CBD), a phytocannabinoid present in Cannabis sativa, presents anxiolytic- and antipsychotic-like effects in preclinical and clinical settings. Anxiolytic-like effects of repeated CBD were shown in chronically stressed animals and these effects were parallel with increased hippocampal neurogenesis. However, antidepressant-like effects of repeated CBD administration in non-stressed animals have been scarcely reported. Here we investigated the behavioral consequences of single or repeated CBD administration in non-stressed animals. We also determined the effects of CBD on cell proliferation and neurogenesis in the dentate gyrus (DG) and subventricular zone (SVZ). Single CBD 3 mg/kg administration resulted in anxiolytic-like effect in mice submitted to the elevated plus maze (EPM). In the tail suspension test (TST), single or repeated CBD administration reduced immobility time, an effect that was comparable to those of imipramine (20 mg/kg). Moreover, repeated CBD administration at a lower dose (3 mg/kg) increased cell proliferation and neurogenesis, as seen by an increased number of Ki-67-, BrdU- and doublecortin (DCX)-positive cells in both in DG and SVZ. Despite its antidepressant-like effects in the TST, repeated CBD administration at a higher dose (30 mg/kg) decreased cell proliferation and neurogenesis in the hippocampal DG and SVZ. Our findings show a dissociation between behavioral and proliferative effects of repeated CBD and suggest that the antidepressant-like effects of CBD may occur independently of adult neurogenesis in non-stressed Swiss mice.

View all citing articles on Scopus

View full text

Rapid communicationFluoxetine increases the content of neurotrophic protein S100β in the rat hippocampus

Abstract

Section snippets

Acknowledgements

Brain Res.

Brain Res.

J. Biol. Chem.

Eur. J. Pharmacol.

Rapid communication
Fluoxetine increases the content of neurotrophic protein S100β in the rat hippocampus